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Abstract
Background: Endoscopic sphincterotomy (ES) is a therapeutic technique developed as an advanced application of
endoscopic retrograde cholangiopancreatography (ERCP). An important adverse event associated with this
procedure is hemorrhage, which may sometimes be uncontrollable. We sought to examine whether cap-assisted
hemoclip application is effective in controlling ES–induced hemorrhage.
Methods: In this prospective study, we investigated the outcomes in 10 patients who had uncontrolled ES–induced
hemorrhage and were treated by cap-assisted application of hemoclip with a forward-viewing endoscope.
Results: Nine of the 10 investigated patients were successfully treated using the cap-assisted hemoclip
technique with forward-viewing endoscope, yielding a success rate of 90 %. The patient with hemorrhage
non-responsive to hemoclipping required catheter embolization of the bleeding artery after its identification
by digital subtraction angiography. One of the 10 patients developed mild pancreatitis after the procedure,
but was successfully managed conservatively.
Conclusions: Cap-assisted hemoclip application with a forward-viewing endoscope appears to be an effective
therapeutic modality for achieving hemostasis in cases of ES–induced hemorrhage, without the occurrence of
any severe adverse events; we believe that this method should be considered as an option in the management of
ES–induced hemorrhage.
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Background
Endoscopic retrograde cholangiopancreatography (ERCP)
is routinely used in the diagnosis of conditions involving
the upper gastrointestinal tract, including the bile ducts,
pancreas, and gallbladder. Subsequently, the application of
ERCP was extended to include endoscopic sphincterot-
omy (ES) with a view to manage the detected abnormal-
ities, without the need for invasive surgery. Although
recent improvements in the ES technique have markedly
enhanced the safety of ES, the procedure is still associated
with several adverse events [1–6]. Among all the potential
risks associated with ES, risk of bleeding is a critical
one and could be life threatening [7]. Reports indicate
that 2–12 % of patients undergoing ES develop bleed-
ing [8], with approximately 0.2 % of the patients having
severe bleeding after the procedure [6]. Generally,
most of the hemorrhage occurs during the procedure,
although delayed bleeding could also occur several
hours, or even days, after the procedure [7]. Further,
while minor oozing is relatively common and usually
self-limiting, brisk, pulsatile, or continued bleeding re-
quires immediate management with aggressive hemostatic
measures.
Conventionally, hemostasis management after ES com-
prises epinephrine (1:10,000) injection, compression, and
diathermy. Epinephrine stops bleeding mainly via localized
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vessel contraction and compression. Submucosal epineph-
rine (1:10,000) injection is commonly used to control
acute bleeding after ES and has a high success rate. How-
ever, the rate of re-bleeding is high, at 11–28.5 % [9].
Therefore, the effectiveness of epinephrine injection in
treating severe, acute, and delayed bleeding after ES is not
clear at present. In addition, epinephrine can cause severe
adverse effects, especially those related to cardiac activity.
Therefore, care should be taken during the management
of patients with suspected or confirmed coronary heart
disease or irregular heartbeat [10]. Diathermy is another
treatment method used for acute or delayed bleeding after
ES; it encompasses electrocoagulation and argon plasma
coagulation (APC). Heating probes or bipolar probes
are commonly used in electrocoagulation, which may
lead to adverse events, including necrosis and perfor-
ation; the rate of re-bleeding after electrocoagulation
is as high as 25 %. In addition, duct damage resulting
from electrocoagulation could lead to acute pancrea-
titis. On the other hand, in APC, a jet of ionized
argon gas is directed at the bleeding lesion via the
endoscope, resulting in coagulation. As a procedure
with minimal carbonization and vaporization, APC is
effective in arresting hemorrhage from multiple points.
However, APC is not as effective as epinephrine injection
or hemostatic titanium clips in controlling arterial
hemorrhage [11]. Fully covered metallic biliary stents have
also been applied in the management of ES–induced
hemorrhage and have afforded good outcomes [12]. How-
ever, several factors, including high cost, requirement of
repeat ERCP for the removal of the metallic biliary stent,
and high shift rate, limit the widespread application of this
method in endoscopic hemostasis. In some cases, e.g., in
cases of arterial hemorrhage, all of the abovementioned
treatment methods fail to effectively control bleeding.
The use of the endoscopic hemostatic clip in the man-
agement of hemorrhage in the digestive tract was first
described by Hayashi et al., and has gained widespread
popularity [13, 14]. Lin et al. reported the application of
hemoclip under duodenoscopic guidance in the treat-
ment of 6 cases of severe ES–induced hemorrhage with
a success rate of 88.8 %. In their study, 2 hemoclips were
applied in each case, with the average number of hemo-
clips dropping off being 0.5 [15]. However, the plastic
sheath of the duodenoscope may kink when passing over
the elevator at the bottom of the instrument channel,
leading to failure of clip deployment. This technically
challenging aspect of the use of endoscopic clips has
limited their application in the treatment of ES–induced
hemorrhage [15, 16].
The cap-assisted hemoclip along with forward-viewing
endoscope is widely used in the treatment of digestive
tract bleeding induced by endoscopic mucosal resection
(EMR) and endoscopic submucosal dissection (ESD) and
appears to be effective, especially in treating arterial
bleeding [17, 18]. Thus far, no study on post–ES
management of hemostasis has been reported via the
cap-assisted hemoclip with forward-viewing endoscope,
although this endoscope is more convenient to use than
the duodenoscope. Therefore, we aimed to evaluate the
safety and effectiveness of cap-assisted hemoclip applica-
tion with the forward-viewing endoscope in the treatment
of uncontrolled ES–induced bleeding in this prospective
case study.
Methods
Study design and patients
Between April 2013 and April 2014, all 843 patients pre-
senting to our endoscopic department with uncontrolled
bleeding during or after ERCP and ES at Changhai hos-
pital were prospectively enrolled in this study. Patients
who had previously undergone ES and/or those having
post-surgical anatomical changes were excluded. Among
the remaining patients, 33 developed post–ES bleeding
necessitating treatment and 11 of them had uncontrolled
bleeding (Fig. 1). In one of the 11 cases, Billroth II sur-
gery was required, and therefore, this case was excluded
from further analysis. Thus, 10 patients with uncon-
trolled post–ES hemorrhage bleeding were included in
this study. The characteristics of these patients are pro-
vided in Table 1.
Uncontrolled post–ES bleeding was defined as continued
bleeding despite conventional treatment measures such as
epinephrine (1:10,000) injection, compression for more
than 5 min, and argon plasma coagulation [13]. The time
to endoscopic hemostasis was defined as the total time
from the insertion of the forward-viewing endoscope until
the stoppage of bleeding. Acute bleeding during ES was de-
fined as bleeding observed after incision of the papilla. De-
layed ES–induced bleeding was defined as bleeding
observed with a few hours to days after the ES procedure.
Post-procedural adverse events were defined as adverse
events related to the application of the cap-assisted hemo-
clip in ERCP/ES, including obstructive jaundice, acute
cholangitis, and acute pancreatitis. Acute pancreatitis was
defined as per the criteria specified previously [4]. The
study protocol was approved by the ethical committee of
Changhai hospital. Informed consent was obtained from
all the patients before the start of the procedure.
Procedure of endoscopic hemostasis
The procedure was performed using a forward-viewing
endoscope (GIF-Q260J Olympus, Tokyo, Japan) with a
front-end transparent cap (distal attachment with rim,
MH-593 Olympus, Tokyo, Japan); the endoscope was
advanced into the descending part of duodenum, close
to the major duodenal papilla. The blood clots were then
removed to expose the points of bleeding, and pressure
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was applied on these spots using the edge of the trans-
parent cap and the clip (HX-600-135, Olympus; or
M00522610, Boston-Resolution), and the clip was placed
as close as possible to the point to avoid damage to the
duct. After gentle suctioning via the transparent cap to
centralize the lesion and the surrounding tissue, the
bleeding vessel was clipped. All the ERCP procedures
were performed by three physicians with extensive
experience in ERCP (>200 cases in a year for more
than 8 years).
Data collection
Data were collected from each patient for the following pa-
rameters: patient demographics; comorbidities, including
congenital and acquired hemostatic disorders; indication
for the initial ERCP; treatment administered; hemostasis
Fig. 1 a Duodenoscope show uncontrollable bleeding after ES in a patient with choledocholithiasis; b Identification of the bleeding site using
transparent cap-assisted forward-viewing endoscope; c Hemostasis with hemoclips under transparent cap-assisted viewing with forward-viewing
endoscope; d After 4 days, the duodenoscope shows that the hemoclips are still located in the papillary area and bleeding is absent
Table 1 Clinical features of the patients









64 M Choledocholithiasis N N 110 210 1.2 78 189 N
75 M Choledocholithiasis N N 152 150 1 58 108 N
70 M Choledocholithiasis diverticulum Diabetes Y 120 273 0.9 50 1692 4
74 M Choledocholithiasis Suppurative cholangitis Hypertension Y 127 89 1.7 66 207 1
67 M Choledocholithiasis Diabetes,
Gallstones
N 158 164 1.2 56 611 N
56 M Choledocholithiasis diverticulum N N 124 162 1.3 142 210 N
N
59 F Intraductal papillary mucinous neoplasm N N 89 267 1.4 89 105 1 (before surgery)
55 M Choledocholithiasis diverticulum Hypertension N 130 269 1.2 59 110 2
N
60 M Cholangiocarcinoma N N 110 100 1 64 85 N
70 M Choledocholithiasis N N 98 126 1.5 78 148 N
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treatment techniques; time to hemostasis; treatment out-
comes; and procedural adverse events.
Results
The median age of the 10 enrolled patients was 66 years
(range: 55 to75 years), and 90 % of the patients were
men. Among the patients, eight had choledocholithiasis;
1 each had cholangiocarcinoma, bile duct papilloma, and
cholangitis; and three had diverticula in the parapapillary
region. Two patients had been taking aspirin, which was
discontinued 5 days before the procedure. One patient
had anemia that was corrected by transfusion of one
unit of erythrocyte suspension before the operation.
None of the patients had any evidence of bleeding
diathesis.
All 10 patients underwent cap-assisted hemoclip
placement with forward-viewing endoscope to arrest the
bleeding (Table 2). The average length of the incision
made on the papillary sphincter was 6.6 mm (range:
5–10 mm). Two patients had papillary balloon dila-
tion during the operation. Nine of the patients had
acute bleeding, while one had delayed bleeding. In
seven cases, the bleeding occurred on the left side of
the incision; in two cases, on the right side; and in
one case, on both sides. Three patients required
transfusion (range: 1–4 units). Further, three patients
required plastic biliary stent implantation, while none
required pancreatic stent implantation.
The vascular origins of the hemorrhage were identified
using the forward-viewing endoscope, and hemoclips
were applied to arrest the bleeding (Fig. 1). The average
number of clips used was 3 (range 1–12), and the aver-
age number of clips dropping off was 0.3 (0–2). The
average bleeding time was 17.4 min (2–61 min). The
success rate of hemostasis was 90 %. In the only case in
which the hemoclip failed to establish hemostasis, spurt
bleeding was identified at 3, 6, and 12 points close to the
incision lines. In this case, all the other bleeding controls
methods attempted, including cold saline spray, epi-
nephrine (1:10,000) injection, compression, and APC,
failed. Additionally, 12 clips were applied (2 dropped
off ), but bleeding could not be arrested. Digital subtrac-
tion angiography (DSA) identified the posterior pancre-
atic duodenal artery as the source of the bleeding, and
catheter embolization was subsequently performed to ar-
rest the bleeding. This patient developed mild pancrea-
titis and was managed conservatively for the same. The
patient did not develop any other adverse events related
to clip application.
Discussion
Traditionally, angiographic embolization or surgery is
required when conventional methods of hemostasis
management fail to arrest bleeding. These methods may,
however, lead to clot formation in adjacent vessels and
intestinal mucosal necrosis. The most important limita-
tion to the surgical management of ES–induced bleeding
is the underlying poor general health condition of the
patients. Localized edema often causes enlarged lesions.
In the extreme cases, retroperitoneal hematoma occurs
with the shrinkage of the vessels underneath the mu-
cosa, making them difficult to identify for suturing. The
operative mortality rate in such cases is as high as 9 %
[19]. Recent advances in non-surgical techniques have
reduced the percentage of cases requiring surgical con-
trol of bleeding from 3 to 0.1 %. Further, the mortality
rate associated with non-surgical approaches decreased
from 1 % to below 0.1 % [20]. Thus, the development of
non-surgical alternative approaches would be beneficial
in the management of ES–induced hemorrhage.
Since ERCP is performed via a duodenoscope, normal
hemostasis in cases of ERCP/ES–induced hemorrhage is
generally achieved by duodenoscope-assisted surgery.
Conventional strategies are usually effective in the
Table 2 Treatment outcomes











eventES (mm) Balloon dilation (mm) Acute Delayed
64 M Y (5) Y (8) Y - Left 1 (0) 2 Success y N/A
75 M Y (5) - Y - Left 1 (0) 24 Success y N/A
70 M Y (5) - Y - Both sides 12 (2) 61 Fail n pancreatitis
74 M Y (8) - Y - Left 4 (1) 7 Success n N/A
67 M Y (10) - Y - Right 2 (0) 21 Success y N/A
56 M Y (8) - Y - Left 2 (0) 14 Success n N/A
59 F Y (8) Y (10) - Y Left 3 (0) 7 Success n N/A
55 M Y (5) - Y - Left 1 (0) 20 Success n N/A
60 M Y (5) - Y - Right 2 (0) 9 Success n N/A
70 M Y (7) - Y - Left 2 (0) 9 Success n N/A
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management of ES–induced hemorrhage that is not se-
vere. However, in some cases, most of the conventional
methods fail to arrest the bleeding. Temporary place-
ment of a covered self-expandable biliary stents across
the biliary orifice is another treatment option, but it is
limited by high cost, high shift ratio, and adverse events
such as acute cholecystitis. Hemoclips are being ex-
tensively used to arrest bleeding, but when used with
a duodenoscope, there is risk of developing bile duct
obstruction and pancreatitis due to closure of the bile
duct with clips; and there is technically challenging
nature, only a few studies have been conducted thus
far on using endoscopic hemostatic clips for achieving
hemostasis in ES–induced hemorrhage [15, 16]. The
technical problem is the difficulty in closing the clip
with the duodenoscope when the elevator is fully ele-
vated, with a short-route position of the endoscope;
this is because of the tension created by the elevator
on the clipping device. The designs and features of
the new endoclips are evolving. For example, unlike
older versions of the clips, the Instinct clips possess
combined abilities to rotate, reopen, and reposition
repeatedly, even when used with the duodenoscope.
However, if the rotation ability of the instinct clip
through the duodenoscope is good, the duodenoscope
elevator must be in a half-locked position and not in
the full-locked position [21]. Of course, this problem
may be overcome by using a semi-long route position
of the endoscope and with the elevator slightly re-
leased. However, in cases of massive bleeding, the
visibility in the operative field is not adequate to
identify the location of the bleeder, making it very
difficult to clip with the duodenoscope. The place-
ment of endoclips using side-viewing endoscopes is
technically more difficult and results in misfiring
more often than when used with forward-viewing
endoscopes.
Cap-assisted forward-viewing endoscopy has been fre-
quently used in endoscopic submucosal dissection or
endoscopic mucosal resection for the treatment of
superficial tumors within the digestive tract [22, 23]. The
transparent cap increases the outer diameter and en-
hances the friction at the distal end of the endoscope,
thereby improving the stability of the scope within the
tube. This allows for better visualization of the lesion
site, even at a distance from the mucosa. Additionally, it
could be used to negotiate the mucosal folds that over-
hang the bleeding sites and improve visualization. Fur-
thermore, the transparent cap would help counter the
acute angle formed after intestinal anastomosis [24, 25].
Considering these points, we tested the feasibility of
cap-assisted hemoclip application with the forward-
viewing endoscope in the treatment of uncontrollable
ES–induced bleeding.
We investigated 10 cases of uncontrollable ES–induced
bleeding managed with cap-assisted forward-viewing
endoscopy and successfully controlled the hemorrhage
by identifying the bleeding sources and deploying the
hemoclips in 90 % of the enrolled cases. The number of
hemoclips dropping off was relatively low, and the time
to hemostasis was short (Table 2).
We use forward-viewing endoscope (GIF-Q260J
Olympus, Tokyo, Japan) with water jet function. We
noticed that it was very useful for the hemostasis proced-
ure. The water jet function is useful for identification of
the bleeding point and establishment of hemostasis by
washing out the extravasated blood, especially in
cases of massive bleeding. However, the duodenoscope
does not offer these advantages. Therefore, we think
this is another reason justifying the use of the forward-
viewing endoscope.
Bleeding sources at the right side of the incision are
associated with potential risk of damage to the pancre-
atic duct when applying the hemoclips since the duct
opens to the right side of the incision. However, it is un-
clear whether hemoclips can cause damage to the open-
ing of the pancreatic duct and lead to pancreatitis. In
two of our cases, the sources of bleeding were located
on the right side of the incision. The excessive bleeding,
incision on the papillary sphincter, and endoscopic bal-
loon dilation make it difficult to determine the position
of the opening of the pancreatic duct. However, even
without locating the opening of the pancreatic duct, no
adverse events, such as acute pancreatitis, were noted
after hemostasis was established in our cases. If the ES–
induced bleeding is not stopped effectively, patients have
to undergo the additional procedures of DSA and sur-
gery, which increases morbidity, cost, and risk of mor-
tality from severe bleeding. Therefore, we recommend
that the establishment of hemostasis and bleeding con-
trol be prioritized over the identification of the opening
of the pancreatic duct, in cases where the latter is diffi-
cult. Appropriate postoperative care should be adminis-
tered, depending on whether there are any adverse
events, such as acute pancreatitis.
The major duodenal papilla receives it blood supply
from the superior pancreaticoduodenal artery, inferior
pancreaticoduodenal artery, and the communicating ar-
tery between these arteries [26]. Most of the arterial sup-
ply is distributed at anterior superior quadrant and
posterior inferior quadrant. About 4 % of the patients
have an abnormal branch of the inferior pancreaticoduo-
denal artery at the region of the incision, which can lead
to severe bleeding after the papilla is incised. In seven of
the 10 cases in this study, the bleeding sources were
located on the left side of the incision, which may be
related to the presence of the branch of the inferior pan-
creaticoduodenal artery.
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Acute ES–induced bleeding has been associated with
several risk factors, including hard stones, diverticula in
parapapillary region, and accidental puncturing of a vessel
by the needle-knife [27]. Delayed ES–induced bleeding, on
the other hand, has been associated with coagulation
abnormalities, heparin therapy, non-steroidal anti-
inflammatory drug use, chronic liver and kidney dys-
function, hypertension, and ischemic heart disease [9].
The use of anticoagulants and antiplatelet medicine
alone has not been reported as the sole risk factor
[2]. In fact, the European Society for Gastrointestinal
Endoscopy recommends that the use of aspirin and
other non-steroidal anti-inflammatory drugs be continued,
especially for patients with high risk of thromboembolism,
since no obvious correlation was noted between these
medications and the possibility of ES–induced bleeding
[28]. In this study, two patients had been receiving oral as-
pirin and one each had anemia, reduced platelet count,
and reduced international normalized ratio. One of the
limitations of this study is that the small sample popula-
tion in this study did not permit the determination of
whether the use of anticoagulants and antiplatelet medi-
cines was a risk factor for ES–induced bleeding.
Conclusion
In conclusion, this is the first study on hemoclip applica-
tion under cap-assisted forward-viewing endoscopic cover
in the management of uncontrollable ES–induced bleed-
ing. Our study revealed that this method was effective in
controlling the bleeding, especially when the bleeding
sources were along the incision, and that the method was
relatively safe with minimal and mild adverse events. Fur-
ther investigations in a larger population from multiple
centers are necessary to confirm our findings.
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